Cogentis Therapeutics Blog
Introductions
Cogentis Therapeutics has been busy since winning our category in the Neuro StartUp Challenge. The day that the NSC winners were announced, Cogentis was in San Francisco, making our final presentation in the OBR/SROne OneStart Competition. We were a finalist team, and while we didn't win the grand prize that evening, we joined a great community of sibling companies and talented mentors.
The day prior to the NSC's announcement, we found out that we had been accepted into the prestigious MassChallenge accelerator as MassChallenge finalists. In July Chris Burch, one of the founders of Cogentis, moved to Boston for the duration of the accelerator program. We now have a lovely desk (next to a window!) in an awesome co-working space. We're surrounded by 127 other teams from around the world, and have continued to build out our team of mentors and industry contacts.
We've spoken with several pharmaceutical companies, philanthropic organizations, venture capital groups, angel syndicates, and research firms. With their feedback, we've developed our research operations plan to take advantage of our skills and leverage the funding that we have.
We hope that our research can start soon, and that we can begin our first steps on the path to end dementia and related neurodegenerative diseases.
Cogentis Therapeutics has been busy since winning our category in the Neuro StartUp Challenge. The day that the NSC winners were announced, Cogentis was in San Francisco, making our final presentation in the OBR/SROne OneStart Competition. We were a finalist team, and while we didn't win the grand prize that evening, we joined a great community of sibling companies and talented mentors.
The day prior to the NSC's announcement, we found out that we had been accepted into the prestigious MassChallenge accelerator as MassChallenge finalists. In July Chris Burch, one of the founders of Cogentis, moved to Boston for the duration of the accelerator program. We now have a lovely desk (next to a window!) in an awesome co-working space. We're surrounded by 127 other teams from around the world, and have continued to build out our team of mentors and industry contacts.
We've spoken with several pharmaceutical companies, philanthropic organizations, venture capital groups, angel syndicates, and research firms. With their feedback, we've developed our research operations plan to take advantage of our skills and leverage the funding that we have.
We hope that our research can start soon, and that we can begin our first steps on the path to end dementia and related neurodegenerative diseases.
